Elotuzumab in Previously Treated Multiple Myeloma

On November 30, 2015, elotuzu­mab (Empliciti) was approved for use in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. 

Videos

Perspectives on the Collaborative Management of Multiple Myeloma

Advertisement

In The News

American Society of Hematology 2016 Annual Meeting

Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I

American Society of Hematology 2016 Annual Meeting

Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy

American Society of Hematology 2016 Annual Meeting

Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

American Society of Hematology 2016 Annual Meeting

Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)

American Society of Hematology 2016 Annual Meeting

Abstract 537: Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry

View all >

In The Literature

Br J Haematol.

Elotuzumab in combination with thalidomide and low-dose dexamethasone

Leukemia

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Bone Marrow Transplant

Autologous stem cell transplant for multiple myeloma patients 70 years or older

Ann Hematol.

Observational study of multiple myeloma in Latin America

J Clin Oncol

Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma

View all >